1C3R image
Deposition Date 1999-07-28
Release Date 1999-09-15
Last Version Date 2024-02-07
Entry Detail
PDB ID:
1C3R
Keywords:
Title:
CRYSTAL STRUCTURE OF AN HDAC HOMOLOG COMPLEXED WITH TRICHOSTATIN A
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.25
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:HDLP (HISTONE DEACETYLASE-LIKE PROTEIN)
Gene (Uniprot):acuC1
Mutations:C75S, C77S
Chain IDs:A, B
Chain Length:375
Number of Molecules:2
Biological Source:Aquifex aeolicus
Primary Citation
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Nature 401 188 193 (1999)
PMID: 10490031 DOI: 10.1038/43710

Abstact

Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumours in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.

Legend

Protein

Chemical

Disease

Primary Citation of related structures